Sangamo Therapeutics Inc (LTS:0R1D)
$ 2.18 -0.06 (-2.68%) Market Cap: 492.41 Mil Enterprise Value: 480.93 Mil PE Ratio: 0 PB Ratio: 12.55 GF Score: 41/100

Q3 2021 Sangamo Therapeutics Inc Earnings Call Transcript

Nov 04, 2021 / 01:15PM GMT
Release Date Price: $11.03 (+20.41%)
Operator

Thank you all for standing by, and welcome to the Sangamo Third Quarter 2021 Teleconference Call. (Operator Instructions) Please also note that today's call is being recorded.

I'll now turn the call over to your host, Aron Feingold, Head of Corporate Communications. Ma'am, you may now begin.

Aron Feingold
Sangamo Therapeutics, Inc. - Head of Corporate Communications & IR Officer

Good morning, and thank you for joining us today. With me this morning on this call are several members of the Sangamo executive leadership team, including Sandy Macrae, Chief Executive Officer; Mark McClung, Chief Operating Officer; Prathyusha Duraibabu, Chief Financial Officer; Jason Fontenot, Chief Scientific Officer; Rob Schott, Head of Development; and Bettina Cockroft, Chief Medical Officer. Slides from our corporate presentation can be found on our website, sangamo.com, under the Investors & Media section under the Events and Presentations page.

This call includes forward-looking statements regarding Sangamo's current expectations. These statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot